Loading people...
Eric Snyder invests in companies within the life sciences sector, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health.
Eric Snyder works at Novo Ventures, a leading venture capital firm focused on life sciences investments.
Eric Snyder is a Partner at Novo Holdings in New York, where he focuses on venture investments within the life sciences and biotechnology sectors. Since joining the firm's United States venture arm in March 2018, he has directed capital toward healthcare innovation and therapeutic development. Prior to his transition into venture capital, Snyder served as a Managing Director at Navigant Consulting and worked as a management consultant for both McKinsey & Company and Leerink Partners. His corporate experience also includes a tenure in global market analytics and business development at Pfizer. He holds a doctorate in neuroscience from Brown University and completed post-doctoral research at Rockefeller University's Fisher Center for Alzheimer's Disease. Today, Snyder leverages his extensive clinical research and strategic consulting background to identify and support emerging therapeutics companies across the healthcare industry.
Eric Snyder serves as a Principal at Novo Ventures, a prominent venture capital firm renowned for its strategic investments in the life sciences sector. In this pivotal role, Eric is instrumental in identifying, evaluating, and supporting innovative companies that are poised to make significant advancements in healthcare and biotechnology. His responsibilities encompass a broad spectrum of activities, including deal sourcing, conducting rigorous due diligence, and actively managing portfolio companies to foster their growth and success.
At Novo Ventures, Eric Snyder's investment focus is primarily directed towards groundbreaking opportunities within life sciences. This includes biotechnology, pharmaceuticals, medical devices, diagnostics, and emerging areas like digital health. He is particularly interested in companies developing novel therapies, disruptive technologies, and solutions that address unmet medical needs. Eric's expertise lies in discerning the scientific merit and commercial viability of early-stage to growth-stage ventures, ensuring that Novo Ventures allocates capital to companies with the highest potential for impact and return. His work directly contributes to accelerating the development of new treatments and improving patient outcomes globally.
While specific details of Eric Snyder's career background are not publicly detailed, his role as a Principal at a leading life sciences venture firm suggests a robust foundation in both scientific understanding and financial acumen. It is common for professionals in his position to possess prior experience in scientific research, investment banking, corporate development within the biotech industry, or previous roles in venture capital. This diverse background equips him with the unique ability to bridge the gap between complex scientific innovation and sound investment strategy, making informed decisions that drive the firm's portfolio forward.
Novo Ventures has a distinguished track record of backing transformative companies, and Eric Snyder plays a key role in continuing this legacy. While individual investment specifics are often proprietary, his contributions are vital to the firm's overall strategy of building a robust portfolio of companies that are at the forefront of medical innovation. Eric's commitment to fostering scientific breakthroughs ensures that Novo Ventures remains a leader in supporting the next generation of life science leaders, ultimately shaping the future of healthcare through strategic capital deployment and active mentorship.
